Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Current Liabilities: 2013-2024

Historic Total Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $173.8 million.

  • Amphastar Pharmaceuticals' Total Current Liabilities rose 29.07% to $205.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.2 million, marking a year-over-year increase of 29.07%. This contributed to the annual value of $173.8 million for FY2024, which is 22.91% down from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Total Current Liabilities is $173.8 million, which was down 22.91% from $225.4 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Total Current Liabilities peaked at $225.4 million during FY2023, and registered a low of $94.9 million during FY2022.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Total Current Liabilities value was $173.8 million (recorded in 2024), while the average stood at $164.7 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 137.62% in 2023, then declined by 22.91% in 2024.
  • Amphastar Pharmaceuticals' Total Current Liabilities (Yearly) stood at $112.2 million in 2020, then declined by 7.48% to $103.8 million in 2021, then fell by 8.62% to $94.9 million in 2022, then soared by 137.62% to $225.4 million in 2023, then fell by 22.91% to $173.8 million in 2024.